Skip to Main Content

Paper Details

Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
Clin Gastroenterol Hepatol
6
2023
CD, Crohn's Disease, Crohn's disease, IBD, TNF-?, inflammatory bowel disease, patients, tumor necrosis factor, ustekinumab, vedolizumab
Adult, Biological Products, Biological Therapy, Cohort Studies, Crohn Disease, Humans, Inflammatory Bowel Diseases, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor Inhibitors, Tumor Necrosis Factor-alpha, Ustekinumab
Author NameAffiliation
Siddharth SinghUniversity of California San Diego
Jihoon KimUniversity of California San Diego
Jiyu LuoUniversity of California San Diego
Paulina PaulUniversity of California San Diego
Vivek A RudrapatnaUniversity of California San Francisco
Sunhee ParkUniversity of California Irvine
Kai ZhengUniversity of California Irvine
Gaurav Syal
Christina HaMayo Clinic
Phillip Fleshner
Dermot P B McGovern
Dermot P B McGovern
Jenny SaukUniversity of California Los Angeles
Berkeley N LimketkaiUniversity of California Los Angeles
Parambir S DulaiNorthwestern University
Brigid S BolandUniversity of California San Diego
Brigid S BolandUniversity of California San Diego
Samuel EisensteinUniversity of California San Diego
Sonia RamamoorthyUniversity of California San Diego
Sonia RamamoorthyUniversity of California San Diego
Gil Y Melmed
Uma MahadevanUniversity of California San Francisco
William J SandbornUniversity of California San Diego
Lucila Ohno-MachadoUniversity of California San Diego
Lucila Ohno-MachadoUniversity of California San Diego
  • 1 - 25

Datasets

Release 1.2